Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice

Clinical Immunology

Volumn 126, Issue 2, 2008, Pages 140-147

  Ansari, Mohammed Javeed I ^a   Fiorina, Paolo ^a,b   Dada, Shirine ^a   Guleria, Indira ^a   Ueno, Takuya ^a,c   Yuan, Xueli ^a   Trikudanathan, Subbulaxmi ^a   Smith, R Neal ^c   Freeman, Gordon ^d   Sayegh, Mohamed H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Autoimmune diabetes; Costimulation; ICOS; Islet transplantation; NOD mice; Sirolimus

Indexed keywords

ICOS MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; RAPAMYCIN; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL SURVIVAL; CELL TRANSPLANTATION; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 38049069792     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.07.019     Document Type: Article

References (33)

1. Eisenbarth G.S. Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 314 (1986) 1360-1368
2. Shapiro A.M., Lakey J.R., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., Kneteman N.M., and Rajotte R.V. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343 (2000) 230-238
3. Jaeger C., Brendel M.D., Hering B.J., Eckhard M., and Bretzel R.G. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 46 (1997) 1907-1910
4. Stegall M.D., Lafferty K.J., Kam I., and Gill R.G. Evidence of recurrent autoimmunity in human allogeneic islet transplantation. Transplantation 61 (1996) 1272-1274
5. Makhlouf L., Kishimoto K., Smith R.N., Abdi R., Koulmanda M., Winn H.J., Auchincloss Jr. H., and Sayegh M.H. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes 51 (2002) 3202-3210
6. Atkinson M.A., and Leiter E.H. The NOD mouse model of type 1 diabetes: as good as it gets?. Nat. Med. 5 (1999) 601-604
7. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., and Bluestone J.A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346 (2002) 1692-1698
8. Rothstein D.M., and Sayegh M.H. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol. Rev. 196 (2003) 85-108
9. Hutloff A., Dittrich A.M., Beier K.C., Eljaschewitsch B., Kraft R., Anagnostopoulos I., and Kroczek R.A. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397 (1999) 263-266
10. McAdam A.J., Chang T.T., Lumelsky A.E., Greenfield E.A., Boussiotis V.A., Duke-Cohan J.S., Chernova T., Malenkovich N., Jabs C., Kuchroo V.K., Ling V., Collins M., Sharpe A.H., and Freeman G.J. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4(+) T cells. J. Immunol. 165 (2000) 5035-5040
11. Yoshinaga S.K., Whoriskey J.S., Khare S.D., Sarmiento U., Guo J., Horan T., Shih G., Zhang M., Coccia M.A., Kohno T., Tafuri-Bladt A., Brankow D., Campbell P., Chang D., Chiu L., Dai T., Duncan G., Elliott G.S., Hui A., McCabe S.M., Scully S., Shahinian A., Shaklee C.L., Van G., Mak T.W., et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 402 (1999) 827-832
12. Ozkaynak E., Gao W., Shemmeri N., Wang C., Gutierrez-Ramos J.C., Amaral J., Qin S., Rottman J.B., Coyle A.J., and Hancock W.W. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat. Immunol. 2 (2001) 591-596
13. Kosuge H., Suzuki J., Gotoh R., Koga N., Ito H., Isobe M., Inobe M., and Uede T. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 75 (2003) 1374-1379
14. Harada H., Salama A.D., Sho M., Izawa A., Sandner S.E., Ito T., Akiba H., Yagita H., Sharpe A.H., Freeman G.J., and Sayegh M.H. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J. Clin. Invest. 112 (2003) 234-243
15. Nanji S.A., Hancock W.W., Anderson C.C., Adams A.B., Luo B., Schur C.D., Pawlick R.L., Wang L., Coyle A.J., Larsen C.P., and Shapiro A.M. Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am. J. Transp. 4 (2004) 526-536
16. Rottman J.B., Smith T., Tonra J.R., Ganley K., Bloom T., Silva R., Pierce B., Gutierrez-Ramos J.C., Ozkaynak E., and Coyle A.J. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat. Immunol. 2 (2001) 605-611
17. Iwai H., Kozono Y., Hirose S., Akiba H., Yagita H., Okumura K., Kohsaka H., Miyasaka N., and Azuma M. Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J. Immunol. 169 (2002) 4332-4339
18. Herman A.E., Freeman G.J., Mathis D., and Benoist C. CD4+CD25+T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J. Exp. Med. 199 (2004) 1479-1489
19. Nanji S.A., Hancock W.W., Luo B., Schur C.D., Pawlick R.L., Zhu L.F., Anderson C.C., and Shapiro A.M. Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes 55 (2006) 27-33
20. Markees T.G., Serreze D.V., Phillips N.E., Sorli C.H., Gordon E.J., Shultz L.D., Noelle R.J., Woda B.A., Greiner D.L., Mordes J.P., and Rossini A.A. NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes 48 (1999) 967-974
21. Kukreja A., Cost G., Marker J., Zhang C., Sun Z., Lin-Su K., Ten S., Sanz M., Exley M., Wilson B., Porcelli S., and Maclaren N. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109 (2002) 131-140
22. Makhlouf L., Yamada A., Ito T., Abdi R., Ansari M.J., Khuong C.Q., Winn H.J., Auchincloss Jr. H., and Sayegh M.H. Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic mice. J. Am. Soc. Nephrol. 14 (2003) 2168-2175
23. Ansari M.J., Salama A.D., Chitnis T., Smith R.N., Yagita H., Akiba H., Yamazaki T., Azuma M., Iwai H., Khoury S.J., Auchincloss Jr. H., and Sayegh M.H. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198 (2003) 63-69
24. Lenschow D.J., Ho S.C., Sattar H., Rhee L., Gray G., Nabavi N., Herold K.C., and Bluestone J.A. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181 (1995) 1145-1155
25. Guo L., Fujino M., Kimura H., Funeshima N., Kitazawa Y., Harihara Y., Tezuka K., Makuuchi M., Suzuki S., and Li X.K. Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation. Transpl. Immunol. 12 (2003) 41-48
26. Guo L., Li X.K., Funeshima N., Fujino M., Nagata Y., Kimura H., Amemiya H., Enosawa S., Tsuji T., Harihara Y., Makuuchi M., and Suzuki S. Prolonged survival in rat liver transplantation with mouse monoclonal antibody against an inducible costimulator (ICOS). Transplantation 73 (2002) 1027-1032
27. Nakamura Y., Yasunami Y., Satoh M., Hirakawa E., Katsuta H., Ono J., Kamada M., Todo S., Nakayama T., Taniguchi M., and Ikeda S. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. Transplantation 75 (2003) 1115-1118
28. Taylor P.A., Panoskaltsis-Mortari A., Freeman G.J., Sharpe A.H., Noelle R.J., Rudensky A.Y., Mak T.W., Serody J.S., and Blazar B.R. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood 105 (2005) 3372-3380
29. Kashizuka H., Sho M., Nomi T., Ikeda N., Kuzumoto Y., Akashi S., Tsurui Y., Mizuno T., Kanehiro H., Yagita H., Nakajima Y., and Sayegh M.H. Role of the ICOS-B7h costimulatory pathway in the pathophysiology of chronic allograft rejection. Transplantation 79 (2005) 1045-1050
30. Luo B., Chan W.F., Lord S.J., Nanji S.A., Rajotte R.V., Shapiro A.M., and Anderson C.C. Diabetes induces rapid suppression of adaptive immunity followed by homeostatic T-cell proliferation. Scand. J. Immunol. 65 (2007) 22-31
31. Shapiro A.M., Suarez-Pinzon W.L., Power R., and Rabinovitch A. Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. Diabetologia 45 (2002) 224-230
32. Rabinovitch A., Suarez-Pinzon W.L., Shapiro A.M., Rajotte R.V., and Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 51 (2002) 638-645
33. Baeder W.L., Sredy J., Sehgal S.N., Chang J.Y., and Adams L.M. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin. Exp .Immunol. 89 (1992) 174-178